These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 30629620

  • 21. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S, Hillier K, Lim GH, Harris TM, Wilson SE, Deeks SL.
    PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
    [Abstract] [Full Text] [Related]

  • 22. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M, Christopoulou D, Schmitt HJ.
    BMC Infect Dis; 2015 Oct 14; 15():419. PubMed ID: 26468008
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.
    Clin Ther; 2013 Feb 14; 35(2):119-34. PubMed ID: 23312274
    [Abstract] [Full Text] [Related]

  • 24. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB.
    JAMA Pediatr; 2015 Jul 14; 169(7):646-52. PubMed ID: 25938798
    [Abstract] [Full Text] [Related]

  • 25. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH, Chiang CS, Chiu CH, Chou P, Lin TY.
    Pediatr Infect Dis J; 2015 Mar 14; 34(3):e71-7. PubMed ID: 25247584
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, Bergsaker MR.
    Vaccine; 2008 Jun 19; 26(26):3277-81. PubMed ID: 18456376
    [Abstract] [Full Text] [Related]

  • 27. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P.
    Clin Infect Dis; 2014 Oct 15; 59(8):1066-73. PubMed ID: 25034421
    [Abstract] [Full Text] [Related]

  • 28. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
    Ricketson LJ, Conradi NG, Vanderkooi OG, Kellner JD.
    Pediatr Infect Dis J; 2018 Jan 15; 37(1):22-27. PubMed ID: 28737622
    [Abstract] [Full Text] [Related]

  • 29. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA, Kilpi TM, Rinta-Kokko H, Nohynek H, Toropainen M, Nuorti JP, Jokinen J.
    Pediatrics; 2015 Jul 15; 136(1):e22-7. PubMed ID: 26077477
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, Jayasinghe S, Giele C, de Klerk N, Andrews RM, McIntyre PB, ACIR linkage Investigator Team.
    Vaccine; 2018 May 03; 36(19):2650-2656. PubMed ID: 29627233
    [Abstract] [Full Text] [Related]

  • 31. Early Declines in Vaccine Type Pneumococcal Carriage in Children Less Than 5 Years Old After Introduction of 10-valent Pneumococcal Conjugate Vaccine in Mozambique.
    Sigaúque B, Moiane B, Massora S, Pimenta F, Verani JR, Mucavele H, Chaúque A, Quintó L, Dos Santos RT, Carvalho MDG, Whitney CG, Lessa FC.
    Pediatr Infect Dis J; 2018 Oct 03; 37(10):1054-1060. PubMed ID: 30216295
    [Abstract] [Full Text] [Related]

  • 32. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
    Nzenze SA, Madhi SA, Shiri T, Klugman KP, de Gouveia L, Moore DP, Karstaedt AS, Tempia S, Nunes MC, von Gottberg A.
    Am J Epidemiol; 2017 Aug 15; 186(4):435-444. PubMed ID: 28482004
    [Abstract] [Full Text] [Related]

  • 33. Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
    Nuorti JP, Rinta-Kokko H, Toropainen M, Siira L, Nohynek H, Palmu AA.
    Vaccine; 2022 Sep 29; 40(41):5950-5958. PubMed ID: 36075797
    [Abstract] [Full Text] [Related]

  • 34. Pneumococcal disease in South Australia: vaccine success but no time for complacency.
    Johnson DR, D'Onise K, Holland RA, Raupach JC, Koehler AP.
    Vaccine; 2012 Mar 09; 30(12):2206-11. PubMed ID: 22273663
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, de Miguel S, Guevara M, MacDonald L, Kozakova J, Slotved HC, Fry NK, Pekka Nuorti J, Danis K, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Colzani E, Pastore Celentano L, Hanquet G, SpIDnet VE study group.
    Vaccine; 2022 Jun 23; 40(29):3963-3974. PubMed ID: 35637067
    [Abstract] [Full Text] [Related]

  • 36. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA.
    Dan Med J; 2015 Jul 23; 62(7):. PubMed ID: 26183055
    [Abstract] [Full Text] [Related]

  • 37. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP.
    Pediatr Infect Dis J; 2013 Feb 23; 32(2):e45-53. PubMed ID: 23080290
    [Abstract] [Full Text] [Related]

  • 38. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
    Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CM, de Cunto Brandileone MC, Almeida SC, Toscano CM, Bierrenbach AL.
    Hum Vaccin Immunother; 2016 Feb 23; 12(2):285-92. PubMed ID: 26905679
    [Abstract] [Full Text] [Related]

  • 39. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R.
    Vaccine; 2014 Jun 05; 32(27):3452-9. PubMed ID: 24690148
    [Abstract] [Full Text] [Related]

  • 40. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
    Brandileone MC, Zanella RC, Almeida SCG, Brandao AP, Ribeiro AF, Carvalhanas TMP, Sato H, Andrade AL, Verani JR, Pneumococcal Carriage Study Group.
    Vaccine; 2016 Nov 04; 34(46):5604-5611. PubMed ID: 27692770
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.